{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:13:57Z","timestamp":1774084437299,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3564,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Schering-Plough International; Oncologia Ca'Granda Onlus (OCGO) Fondazione"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1093\/annonc\/mdp343","type":"journal-article","created":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T00:30:30Z","timestamp":1253320230000},"page":"655-661","source":"Crossref","is-referenced-by-count":78,"title":["Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study"],"prefix":"10.1016","volume":"21","author":[{"given":"S.","family":"Siena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Danova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Salvagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Schiavetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bajetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp343_bb0010","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0015","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0020","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1634\/theoncologist.12-7-884","article-title":"Multidisciplinary management of brain metastases","volume":"12","author":"Eichler","year":"2007","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdp343_bb0025","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0360-3016(98)00442-8","article-title":"Identification of prognostic factors in patients with brain metastases: a review of 1292 patients","volume":"43","author":"Lagerwaard","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdp343_bb0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdp343_bb0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0360-3016(00)00547-2","article-title":"Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases","volume":"47","author":"Gaspar","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdp343_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1012226718323","article-title":"A phase II trial of temozolomide for patients with recurrent or progressive brain metastases","volume":"53","author":"Abrey","year":"2001","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdp343_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1008354323167","article-title":"Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases","volume":"12","author":"Christodoulou","year":"2001","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdp343_bb0050","first-page":"111","article-title":"A phase I\/II trial of topotecan and radiation therapy for CNS-metastases of patients with solid tumors","volume":"22","author":"Hedde","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14737140.1.1.13","article-title":"Temozolomide: a novel oral alkylating agent","volume":"1","author":"Danson","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdp343_bb0060","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0959-8049(96)00258-4","article-title":"The Charing Cross Hospital experience with temozolomide in patients with gliomas","volume":"32A","author":"Newlands","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0065","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp343_bb0070","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1383-5742(00)00016-8","article-title":"Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents","volume":"462","author":"Bignami","year":"2000","journal-title":"Mutat Res"},{"key":"10.1093\/annonc\/mdp343_bb0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.onc.1209785","article-title":"Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine","volume":"26","author":"Roos","year":"2007","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdp343_bb0085","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","article-title":"Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules","volume":"88","author":"Tolcher","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0090","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjc.6603376","article-title":"Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)","volume":"95","author":"Brandes","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0095","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2007.10.7722","article-title":"Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma","volume":"25","author":"Wick","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1081\/CNV-120001173","article-title":"First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study","volume":"20","author":"Bernardo","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdp343_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000066520","article-title":"Front-line paclitaxel\/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer","volume":"64","author":"Cortes","year":"2003","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdp343_bb0110","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","article-title":"Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study","volume":"85","author":"Franciosi","year":"1999","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ijrobp.2007.01.004","article-title":"A phase I\/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors","volume":"68","author":"Hedde","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdp343_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.9-1-68","article-title":"The role of topotecan in the treatment of brain metastases","volume":"9","author":"Wong","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdp343_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0130","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdl148","article-title":"Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG\/ADO study","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0135","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study","volume":"22","author":"Agarwala","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0140","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/annonc\/mdl056","article-title":"Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada\u2013Clinical Trials Group (NCIC-CTG)","volume":"17","author":"Trudeau","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-004-9176-0","article-title":"Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study","volume":"71","author":"Christodoulou","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdp343_bb0150","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1179\/joc.2007.19.5.582","article-title":"Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer","volume":"19","author":"Onyenadum","year":"2007","journal-title":"J Chemother"},{"key":"10.1093\/annonc\/mdp343_bb0155","first-page":"361","article-title":"Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors","volume":"30","author":"Kouvaris","year":"2007","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdp343_bb0160","first-page":"2259","article-title":"Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale)","volume":"26","author":"Lorusso","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdp343_bb0165","first-page":"894","article-title":"Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme","volume":"5","author":"Chang","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0170","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ijrobp.2007.07.2366","article-title":"Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines","volume":"69","author":"van Nifterik","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdp343_bb0175","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","article-title":"Current management of brain metastases, with a focus on systemic options","volume":"23","author":"Langer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0180","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2002.04.140","article-title":"Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases","volume":"20","author":"Antonadou","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2407-7-18","article-title":"Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life","volume":"7","author":"Addeo","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdp343_bb0190","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2004.00.1768","article-title":"Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases","volume":"24","author":"Suh","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0195","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.12-7-766","article-title":"Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors","volume":"12","author":"Gori","year":"2007","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdp343_bb0200","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2005.05.249","article-title":"Survival after brain metastases from breast cancer in the trastuzumab era","volume":"23","author":"Kirsch","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0205","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/jco.2007.25.18_suppl.1012","article-title":"EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)","volume":"25","author":"Lin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp343_bb0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ncponc0931","article-title":"CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation","volume":"4","author":"Pan","year":"2007","journal-title":"Nat Clin Pract Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341938305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341938305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/3\/655\/396584\/mdp343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:14:34Z","timestamp":1624518874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341938305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S092375341938305X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp343","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}